Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesContineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. Class A Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
10.3 USD 0.78 ( 8.19%)
Last update at 2026-11-09T21:00:00Z
VOLUME
263229
Market Cap
519.92M

Momentum Score

…

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.32
Low
10.50
High
52 Week Price Range
8.60
Low
17.79
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for Contineum Therapeutics, Inc. are limited and do not clearly describe its operations or product pipeline, so external information about the company's core activities is sparse. Where a company in the therapeutics space operates, long-term growth typically depends on clinical development progress, regulatory approvals, intellectual property and strategic partnerships, which could support future value creation and investor interest.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
9.52
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.03
ROE
-28.00%
Net Debt
-67.35M
ROCE
-25.62%
Diluted EPS TTM
-1.60

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -59.98M -42.26M 23.17M -24.25M -29.00M
Net income -59.98M -42.26M 22.72M -24.25M -29.00M
Selling general administrative 16.54M 12.47M 6.32M 5.83M 6.29M
Gross profit -0.32M -0.26M - - -
Reconciled depreciation 0.32M 0.26M 0.20M 0.33M 0.33M
Ebit -68.38M -42.26M - - -
Ebitda -68.06M -42.00M - - -
Depreciation and amortization 0.32M 0.26M - - -
Operating income -68.06M -50.89M 16.08M -22.72M -28.65M
Other operating expenses 68.06M 50.89M - - -
Interest expense - 0.00M 0.21M 0.39M 0.33M
Tax provision - 0.00M 0.45M 0.00M -
Interest income 8.25M 8.90M 4.61M 0.76M 0.08M
Net interest income 8.25M 8.90M 4.40M 0.37M -0.26M
Total revenue 0.00M 0.00M 50.00M 0.00M 0.00M
Total operating expenses 68.06M 50.64M 33.92M 22.72M 28.65M
Cost of revenue 0.32M 0.26M - - -
Total other income expense net 8.08M 8.64M 2.69M -1.91M -0.10M
Net income from continuing ops -59.98M -42.26M 22.72M -24.25M -29.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 276.64M 212.85M 130.39M 50.64M 70.52M
Other current assets 5.02M 1.63M 2.52M 1.15M 0.78M
Total liab 15.65M 14.78M 198.32M 143.85M 141.41M
Total stockholder equity 260.99M 198.07M -67.94M -93.21M -70.89M
Other current liab 6.39M 6.71M - - -
Common stock 0.04M 0.03M - - -
Capital stock 0.04M 0.03M 0.00M 0.00M 0.01M
Retained earnings -177.38M -117.40M -75.14M -97.86M -73.61M
Cash 75.60M 21.94M 15.53M 5.57M 4.63M
Total current liabilities 9.74M 9.97M 5.48M 7.55M 3.67M
Net debt -67.35M -15.68M - - 0.28M
Short term debt 2.34M 1.45M - - -
Short long term debt - - - 3.95M 1.25M
Short long term debt total 8.25M 6.26M - - -
Other stockholder equity 438.07M 315.37M - - -
Total current assets 267.92M 206.39M 127.71M 48.39M 69.78M
Short term investments 187.29M 182.82M 109.66M 41.67M 64.37M
Long term debt - - - - 3.66M
Accounts payable 1.02M 1.81M 0.64M 0.43M 0.66M
Accumulated other comprehensive income 0.26M 0.07M - - -
Non currrent assets other 0.26M 0.00M 1.28M 0.13M 0.10M
Non current assets total 8.72M 6.46M 2.68M 2.24M 0.74M
Capital lease obligations 8.25M 6.26M 0.57M 1.90M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -3.48M -69.74M -65.57M 22.30M -64.97M
Total cashflows from investing activities -3.71M -69.74M - - -
Net borrowings - 0.00M - - -
Total cash from financing activities 112.69M 109.00M 56.18M -1.24M 79.84M
Net income -59.98M -42.26M 22.72M -24.25M -29.00M
Change in cash 53.66M 6.42M 9.96M 0.94M -11.39M
Begin period cash flow 21.94M 15.53M 5.57M 4.63M 16.02M
End period cash flow 75.60M 21.94M 15.53M 5.57M 4.63M
Total cash from operating activities -55.31M -32.84M 19.35M -20.12M -26.27M
Issuance of capital stock 112.25M 108.21M 60.14M 0.00M 79.73M
Depreciation 0.32M 0.26M 0.20M 0.33M 0.33M
Other cashflows from investing activities - 0.02M - - -
Sale purchase of stock - 0.00M -0.03M -0.00M 0.00M
Other cashflows from financing activities - 0.79M - - -
Capital expenditures 0.23M 0.51M 0.41M 0.12M 0.17M
Change in working capital -6.04M 5.33M -1.02M -1.27M 0.11M
Stock based compensation 10.04M 6.80M 2.22M 1.93M 1.75M
Other non cash items 0.34M -2.98M -2.10M 2.90M 0.16M
Free cash flow -55.54M -33.36M 18.93M -20.24M -26.43M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CTNM
Contineum Therapeutics, Inc. Class A Common Stock		 0.78
8.19%		 10.30 - - 11.15 2.33 8.25 20.76
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

3565 General Atomics Court, San Diego, CA, United States, 92121

858 333 5280

https://www.contineum-tx.com

51

Name Title Year Born
Mr. Carmine N. Stengone MBA, MS President, CEO, Secretary & Director 1976
Mr. Peter T. Slover CPA Chief Financial Officer 1975
Dr. Daniel S. Lorrain Ph.D. Chief Science Officer 1969
Dr. Stephen L. Huhn F.A.A.P, F.A.C.S., M.D. Chief Medical Officer & Senior VP of Clinical Development 1961
Mr. Austin Chen Ph.D. SVP & Head of Research NA
Mr. Michael Mayberry Senior Director & Corporate Controller NA
Mr. Carmine N. Stengone MBA, MS President, CEO & Director 1976
Mr. John S. Healy General Counsel & Corporate Secretary 1973
Ms. Morgan Paulsen Senior Manager of Accounting NA
Dr. Daniel S. Lorrain Ph.D. Chief Science Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…